How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%

Soleno Therapeutics (SLNO) shares, currently trading at $82.35, are projected by Wall Street analysts to have a mean upside of 43.2% to $117.88. However, the article emphasizes that while price targets suggest significant potential, a more reliable indicator of SLNO's upside is the strong consensus among analysts for substantially higher earnings, evidenced by a 56.7% increase in the Zacks Consensus Estimate over the past month and the stock's Zacks Rank #2. This positive trend in earnings estimate revisions is historically correlated with near-term stock price movements, providing a stronger rationale for potential gains than price targets alone.

Analysis

Soleno Therapeutics (SLNO) exhibits strong indicators of potential near-term upside, driven primarily by significant positive revisions in its earnings estimates rather than its consensus price target. While Wall Street analysts project a mean price target of $117.88, implying a 43.2% upside from its recent close of $82.35, the more compelling evidence lies in the underlying earnings momentum. Over the past month, the Zacks Consensus Estimate for the current year has increased by a substantial 56.7%, a revision based on five upward estimate changes with no corresponding negative revisions. This trend is presented as a more reliable predictor of stock price movement than price targets, which are often subject to institutional biases. The bullish outlook is further supported by the stock's Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked companies and indicating a strong quantitative backing for near-term appreciation.

Key Decisions for Investors

• Investors should weigh the 56.7% increase in the consensus earnings estimate more heavily than the analyst price targets, as this is highlighted as a more reliable indicator of potential near-term stock appreciation.
• Given the combination of strong upward earnings revisions and a Zacks Rank #2 (Buy), investors could consider SLNO as a candidate for a bullish position, especially if their strategy aligns with capturing momentum from positive fundamental shifts.
• It is crucial to monitor for continued positive earnings estimate revisions to validate the investment thesis, while treating the 43.2% potential upside from the mean price target as a secondary, and more speculative, data point.